<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Fabelova L</submitter><funding>Intramural NIH HHS</funding><funding>HSRD VA</funding><funding>European Commission</funding><pagination>137530</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9846180</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>313</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Per- and polyfluoroalkyl substances (PFAS) are persistent organic pollutants. The first exposure to PFAS occurs in utero, after birth it continues via breast milk, food intake, environment, and consumer products that contain these chemicals. Our aim was to identify determinants of PFAS concentrations in sensitive population subgroups- pregnant women and newborns.&lt;h4>Methods&lt;/h4>Nine European birth cohorts provided exposure data on PFAS in pregnant women (INMA-Gipuzkoa, Sabadell, Valencia, ELFE and MoBa; total N = 5897) or newborns (3xG study, FLEHS 2, FLEHS 3 and PRENATAL; total N = 940). PFOS, PFOA, PFHxS and PFNA concentrations were measured in maternal or cord blood, depending on the cohort (FLEHS 2 measured only PFOS and PFOA). PFAS concentrations were analysed accor</pubmed_abstract><journal>Chemosphere</journal><pubmed_title>PFAS levels and exposure determinants in sensitive population groups.</pubmed_title><pmcid>PMC9846180</pmcid><funding_grant_id>TPR 15-230</funding_grant_id><funding_grant_id>ZIA ES044008</funding_grant_id><pubmed_authors>Irizar A</pubmed_authors><pubmed_authors>Morrens B</pubmed_authors><pubmed_authors>Rodriguez Martin L</pubmed_authors><pubmed_authors>Vrijheid M</pubmed_authors><pubmed_authors>Ferguson K</pubmed_authors><pubmed_authors>Fabelova L</pubmed_authors><pubmed_authors>Gilles L</pubmed_authors><pubmed_authors>Patayova H</pubmed_authors><pubmed_authors>Richterova D</pubmed_authors><pubmed_authors>Uhl M</pubmed_authors><pubmed_authors>Casas M</pubmed_authors><pubmed_authors>Dalsager L</pubmed_authors><pubmed_authors>Den Hond E</pubmed_authors><pubmed_authors>Zaros C</pubmed_authors><pubmed_authors>Schettgen T</pubmed_authors><pubmed_authors>Montazeri P</pubmed_authors><pubmed_authors>Palkovicova Murinova L</pubmed_authors><pubmed_authors>Beneito A</pubmed_authors><pubmed_authors>Schoeters G</pubmed_authors><pubmed_authors>Lopez Espinosa MJ</pubmed_authors><pubmed_authors>Villanger GD</pubmed_authors><pubmed_authors>Santa-Marina L</pubmed_authors><pubmed_authors>Colles A</pubmed_authors><pubmed_authors>Dereumeaux C</pubmed_authors><pubmed_authors>Haug LS</pubmed_authors><pubmed_authors>Govarts E</pubmed_authors><pubmed_authors>Rausova K</pubmed_authors></additional><is_claimable>false</is_claimable><name>PFAS levels and exposure determinants in sensitive population groups.</name><description>&lt;h4>Background&lt;/h4>Per- and polyfluoroalkyl substances (PFAS) are persistent organic pollutants. The first exposure to PFAS occurs in utero, after birth it continues via breast milk, food intake, environment, and consumer products that contain these chemicals. Our aim was to identify determinants of PFAS concentrations in sensitive population subgroups- pregnant women and newborns.&lt;h4>Methods&lt;/h4>Nine European birth cohorts provided exposure data on PFAS in pregnant women (INMA-Gipuzkoa, Sabadell, Valencia, ELFE and MoBa; total N = 5897) or newborns (3xG study, FLEHS 2, FLEHS 3 and PRENATAL; total N = 940). PFOS, PFOA, PFHxS and PFNA concentrations were measured in maternal or cord blood, depending on the cohort (FLEHS 2 measured only PFOS and PFOA). PFAS concentrations were analysed accor</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2025-04-03T23:49:16.027Z</modification><creation>2024-11-08T18:06:55.855Z</creation></dates><accession>S-EPMC9846180</accession><cross_references><pubmed>36509187</pubmed><doi>10.1016/j.chemosphere.2022.137530</doi></cross_references></HashMap>